Positioning the life sciences business as a core business
First written in FY2016. 2 of 24 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1Wellness’s share of net sales in the interim period declined from 17.7% to 17.6%.Annual report
「Wellness 13,343 17.7 13,770 17.6」
The Wellness business recorded a 3.2% year-on-year increase in net sales, but its share of net sales declined from 17.7% to 17.6%. - FY2025The Wellness business's share of net sales declined from 19.2% to 18.0%.Annual report
「The Wellness business accounts for 18.0% of net sales and 5.2% of operating profit,」
The Wellness business recorded a 4.0% increase in net sales, but its share of net sales declined from 19.2% in the previous fiscal year to 18.0%. - FY2025-H1The Wellness business's share of net sales declined from 20.0% to 17.7%.Annual report
「Wellness 13,193 20.0 13,343 17.7」
The Wellness business recorded a 1.1% year-on-year increase in net sales, but its share of net sales declined from 20.0% to 17.7%. - FY2024The Wellness business's share of net sales declined from 19.5% to 19.2%.Annual report
「It accounts for 19.2% of net sales and 10.0% of operating profit,」
The Wellness business is positioned as a growth and health-related business, but its share of net sales declined from 20.4% for the cumulative third quarter in the previous disclosure to 19.2% for the full year. - FY2024-Q3The Wellness business's share of net sales declined from 20.4% to 19.5%.Annual report
「Wellness 20,269 20.4 19,832 19.5」
Net sales in the Wellness business decreased from ¥20,269 million in the same period of the previous year to ¥19,832 million, and its share of net sales declined from 20.4% to 19.5%. - FY2024-Q2The Wellness business's share of net sales increased from 19.9% to 20.0%.Annual report
「Wellness 13,169 19.9 13,193 20.0」
Net sales in the Wellness business increased from ¥13,169 million in the same period of the previous year to ¥13,193 million, and its share of net sales rose from 19.9% to 20.0%. - FY2024-Q1The Wellness business's share of net sales increased from 18.9% to 20.9%.Annual report
「Wellness 6,313 18.9 6,672 20.9」
The Wellness business's share of net sales increased from 18.9% in the same period of the previous year to 20.9%. - FY2023The Wellness business's share of net sales increased from 18.8% to 20.9%.Annual report
「The Wellness business accounts for 20.9% of net sales and 22.3% of operating profit,」
The Wellness business's share of net sales increased from 18.8% in the previous fiscal year to 20.9%, while its share of operating profit was 22.3%. - FY2023-Q3The Wellness business's share of net sales increased from 18.3% to 20.4%.Annual report
「Wellness 17,410 18.3 20,269 20.4」
Net sales in the Wellness business increased from ¥17,410 million in the same period of the previous year to ¥20,269 million, and its share of net sales rose from 18.3% to 20.4%. - FY2023-Q2The Wellness business's share of net sales increased from 18.0% to 19.9%.Annual report
「Wellness 11,154 18.0 13,169 19.9」
The Wellness business's share of net sales increased from 18.0% in the same period of the previous year to 19.9%. - FY2023-Q1Updated the quarterly sales mix for the Wellness businessAnnual report
「Wellness 5,767 18.5 6,313 18.9」
The Wellness business's share of net sales increased from 18.5% in the same period of the previous year to 18.9%. - FY2022RestatedAnnual report
「The Wellness business is one of the Group's fastest-growing businesses, accounting for 18.8% of net sales, while the Environmental Solutions business is positioned as one of the Group's core businesses, accounting for 27.5% of net sales,」
Following the reorganisation of the former Life Sciences business, the Wellness business was positioned as a growth business and the Environmental Solutions business as a core business, and their shares of net sales were disclosed. - FY2022-Q3RestatedAnnual report
「In connection with changes to the Group's organisational structure aimed at strongly advancing its medium-term plan, the reporting segments have been changed from the previous 3 segments, "Life Sciences," "Information Electronics" and "Construction and Civil Engineering Materials," to 4 segments: "Wellness," "Environmental Solutions," "Information Electronics" and "Construction and Civil Engineering Materials."」
The disclosure classification separating the former Life Sciences business into the Wellness and Environmental Solutions businesses was reconfirmed. - FY2022-Q2ReframedAnnual report
「The reportable segments were changed from the previous 3 categories, Life Science, Information Electronics and Building and Civil Engineering Materials, to 4 categories: Wellness, Environmental Solutions, Information Electronics and Building and Civil Engineering Materials.」
The former single reportable segment, Life Science, was divided into Wellness and Environmental Solutions, changing the way the business composition is disclosed. - FY2022-Q1Share of net sales declined from 49.5% to 45.7%.Annual report
「Life Science 14,280 45.7」
The Life Science business remained a major business, but its share of net sales declined from 49.5% in the previous fiscal year to 45.7%. - FY2021Share of net sales declined from 49.5% to 48.1%.Annual report
「The Life Science business was positioned as one of our group’s core businesses, accounting for 48.1% of net sales.」
The Life Science business remained a core business, but its share of net sales declined from 49.5% in the previous fiscal year to 48.1%. - FY2021-Q3Share of net sales declined from 49.1% to 48.6%.Annual report
「Life Science 42,290 48.6」
The Life Science business’s share of net sales declined from the previously reported 49.1% to 48.6%. - FY2021-Q2Share of net sales declined from 49.8% to 49.1%.Annual report
「Life Science 28,684 49.1」
The Life Science business’s share of net sales declined from the previously reported 49.8% to 49.1%. - FY2021-Q1Share of net sales rose from 49.5% to 49.8%.Annual report
「Life Science 14,604 49.8」
The Life Science business’s share of net sales rose from 49.5% in the previous fiscal year to 49.8%. - FY2020Share of net sales rose from 48.8% to 49.5%.Annual report
「The Life Science business was positioned as one of our group’s core businesses, accounting for 49.5% of net sales.」
The Life Science business’s share of net sales rose from 48.8% in the previous fiscal year to 49.5%. - FY2019Share of net sales declined from 48.9% to 48.8%.Annual report
「The Life Science business was positioned as one of our group’s core businesses, accounting for 48.8% of net sales.」
The Life Science business’s share of net sales declined from 48.9% in the previous fiscal year to 48.8%. - FY2018Share of net sales edged up to 48.9%.Annual report
「The Life Science business was positioned as one of our group’s core businesses, accounting for 48.9% of net sales.」
The share of net sales rose from the previous 48.8% to 48.9%. - FY2017Share of net sales edged up to 48.8%.Annual report
「The Life Science business was positioned as one of our group’s core businesses, accounting for 48.8% of net sales.」
The Life Science business’s share of net sales rose from the previously reported 48.6% to 48.8%. - FY2016First statedAnnual report
「The Life Science business was positioned as one of our group’s core businesses, accounting for 48.6% of net sales.」
Described the Life Science business as a core business accounting for 48.6% of net sales.